Annovis Bioincis A Clinical Stage Biopharmaceutical Company Dedicated To Developing Therapies For Neurodegenerative Diseasesfounded In 2008 By Drmaria Maccecchinithe Company Is Based In Malvernpennsylvaniaand Focuses On Halting Nerve Cell Death While Restoring Cognitive And Motor Functions In Patients With Conditions Such As Alzheimerae S Disease And Parkinsonae S Disease Annovis Is Advancing A Late Stage Clinical Drug Platform With Several Key Products In Its Pipelinethe Lead Drugbuntanetapis An Oral Small Molecule Designed To Inhibit Neurotoxic Proteins And Improve Synaptic Transmission In Patientsadditionallyanvs405 Is An Intravenous Formulation Aimed At Providing Neuroprotection After Traumatic Brain Injurieswhile Anvs301 Targets Advanced Alzheimerae S Disease To Enhance Cognitive Functionthe Company Emphasizes Translational Research To Validate Drug Efficacy And Aims To Address The Needs Of Patients And Healthcare Providers In Neurology
